The emerging role of MMP14 in brain tumorigenesis and future therapeutics

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 113-120

  Ulasov, Ilya ^a   Yi, Ruiyang ^b   Guo, Donna ^b   Sarvaiya, Purvaba ^b   Cobbs, Charles ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Angiogenesis; Brain; Glioblastoma; Invasion; MMP14; Tumor

Indexed keywords

ALPHAVBETA3 INTEGRIN INHIBITOR; DX 2400; HERMES ANTIGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MARIMASTAT; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; SYNDECAN 1; TEMOZOLOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; ACTINONIN; ANTENNAPEDIA COUPLED CYTOPLASMIC MATRIX METALLOPROTEINASE 14; BIOCHANIN A; DZ13; EPIGALLOCATECHIN GALLATE; GENISTEIN; MICRORNA 9; MINOCYCLINE; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIFS; VITRONECTIN RECEPTOR;

ANGIOGENESIS; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; TUMOR INVASION; ARTHRALGIA; BRAIN TUMOR; CELL INVASION; DRUG TARGETING; GLIOMA; GLIOMA CELL; METASTASIS; NEOPLASM; PAIN; PROGRESSION FREE SURVIVAL; TENDON DISEASE; TENDON PAIN; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS; BRAIN; GLIOBLASTOMA; INVASION; MMP14; TUMOR;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CARCINOGENESIS; GLIOBLASTOMA; HUMANS; MATRIX METALLOPROTEINASE 14; MOLECULAR TARGETED THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901456967     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.03.002     Document Type: Review

References (99)

1. CBTRUS Statistical Report: primary brain tumors in the United States 1992-1997 2000, Central Brain Turmo Registry of the United States, Chicago.
2. Holland E.C. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6242-6244.
3. Chintala S.K., Mohanam S., Go Y., Venkaiah B., Sawaya R., Gokaslan Z.L., Rao J.S. Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor. Mol. Carcinog. 1997, 20:355-365.
4. Rasheed B.K., Wiltshire R.N., Bigner S.H., Bigner D.D. Molecular pathogenesis of malignant gliomas. Curr. Opin. Oncol. 1999, 11:162-167.
5. Louis D.N. A molecular genetic model of astrocytoma histopathology. Brain Pathol. 1997, 7:755-764.
6. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 1985, 44:139-266.
7. Wallner K.E., Galicich J.H., Krol G., Arbit E., Malkin M.G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16:1405-1409.
8. Geho D.H., Bandle R.W., Clair T., Liotta L.A. Physiological mechanisms of tumor-cell invasion and migration. Physiology 2005, 20:194-200.
9. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
10. Ethell I.M., Ethell D.W. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J. Neurosci. Res. 2007, 85:2813-2823.
11. Szabova L., Son M.Y., Shi J., Sramko M., Yamada S.S., Swaim W.D., Zerfas P., Kahan S., Holmbeck K. Membrane-type MMPs are indispensable for placental labyrinth formation and development. Blood 2010, 116:5752-5761.
12. Chintala S.K., Tonn J.C., Rao J.S. Matrix metalloproteinases and their biological function in human gliomas. Int. J. Dev. Neurosci. 1999, 17:495-502.
13. Nakada M., Nakamura H., Ikeda E., Fujimoto N., Yamashita J., Sato H., Seiki M., Okada Y. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am. J. Pathol. 1999, 154:417-428.
14. Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E.W., Foidart J.M., Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 2002, 16:555-564.
15. Barbolina M.V., Stack M.S. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin. Cell Dev. Biol. 2008, 19:24-33.
16. VanMeter T.E., Rooprai H.K., Kibble M.M., Fillmore H.L., Broaddus W.C., Pilkington G.J. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J. Neurooncol. 2001, 53:213-235.
17. Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S.A., Mankani M., Robey P.G., Poole A.R., Pidoux I., Ward J.M., Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
18. Zhou Z., Apte S.S., Soininen R., Cao R., Baaklini G.Y., Rauser R.W., Wang J., Cao Y., Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4052-4057.
19. Gkantidis N., Katsaros C., Chiquet M. Detection of gelatinolytic activity in developing basement membranes of the mouse embryo head by combining sensitive in situ zymography with immunolabeling. Histochem. Cell Biol. 2012, 138:557-571.
20. Quick R.E., Dunlap J.A., Jessen J.R. Expression analysis of zebrafish membrane type-2 matrix metalloproteinases during embryonic development. Gene Expr. Patterns 2012, 12:254-260.
21. Fortunato S.J., Menon R., Lombardi S.J. Expression of a progelatinase activator (MT1-MMP) in human fetal membranes. Am. J. Reprod. Immunol. 1998, 39:316-322.
22. Kaitu'u-Lino T.J., Palmer K.R., Whitehead C.L., Williams E., Lappas M., Tong S. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. Am. J. Pathol. 2012, 180:888-894.
23. Ulbrich S.E., Meyer S.U., Zitta K., Hiendleder S., Sinowatz F., Bauersachs S., Buttner M., Frohlich T., Arnold G.J., Reichenbach H.D., Wolf E., Meyer H.H. Bovine endometrial metallopeptidases MMP14 and MMP2 and the metallopeptidase inhibitor TIMP2 participate in maternal preparation of pregnancy. Mol. Cell. Endocrinol. 2011, 332:48-57.
24. Yamada T., Yoshiyama Y., Sato H., Seiki M., Shinagawa A., Takahashi M. White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathol. 1995, 90:421-424.
25. Lampert K., Machein U., Machein M.R., Conca W., Peter H.H., Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am. J. Pathol. 1998, 153:429-437.
26. Ulasov I., Thaci B., Sarvaiya P., Yi R., Guo D., Auffinger B., Pytel P., Zhang L., Kim C.K., Borovjagin A., Dey M., Han Y., Baryshnikov A.Y., Lesniak M.S. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. Cancer Med. 2013, 2:457-467.
27. Fillmore H.L., VanMeter T.E., Broaddus W.C. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J. Neuro Oncol. 2001, 53:187-202.
28. Yamamoto M., Mohanam S., Sawaya R., Fuller G.N., Seiki M., Sato H., Gokaslan Z.L., Liotta L.A., Nicolson G.L., Rao J.S. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 1996, 56:384-392.
29. Nuttall R.K., Pennington C.J., Taplin J., Wheal A., Yong V.W., Forsyth P.A., Edwards D.R. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol. Cancer Res. 2003, 1:333-345.
30. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
31. Abe T., Mori T., Kohno K., Seiki M., Hayakawa T., Welgus H.G., Hori S., Kuwano M. Expression of 72kDa type IV collagenase and invasion activity of human glioma cells. Clin. Exp. Metastasis 1994, 12:296-304.
32. Toth M., Bernardo M.M., Gervasi D.C., Soloway P.D., Wang Z., Bigg H.F., Overall C.M., DeClerck Y.A., Tschesche H., Cher M.L., Brown S., Mobashery S., Fridman R. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. J. Biol. Chem. 2000, 275:41415-41423.
33. Gingras D., Bousquet-Gagnon N., Langlois S., Lachambre M.P., Annabi B., Beliveau R. Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett. 2001, 507:231-236.
34. Bigg H.F., Morrison C.J., Butler G.S., Bogoyevitch M.A., Wang Z., Soloway P.D., Overall C.M. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res. 2001, 61:3610-3618.
35. Ohuchi E., Imai K., Fujii Y., Sato H., Seiki M., Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 1997, 272:2446-2451.
36. Deryugina E.I., Bourdon M.A., Luo G.X., Reisfeld R.A., Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J. Cell Sci. 1997, 110(Pt 19):2473-2482.
37. Hur J.H., Park M.J., Park I.C., Yi D.H., Rhee C.H., Hong S.I., Lee S.H. Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression. J. Korean Med. Sci. 2000, 15:309-314.
38. Hiraoka N., Allen E., Apel I.J., Gyetko M.R., Weiss S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998, 95:365-377.
39. Pei D., Weiss S.J. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J. Biol. Chem. 1996, 271:9135-9140.
40. Itoh Y., Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol. 2006, 206:1-8.
41. d'Ortho M.P., Will H., Atkinson S., Butler G., Messent A., Gavrilovic J., Smith B., Timpl R., Zardi L., Murphy G. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem. 1997, 250:751-757.
42. Belien A.T., Paganetti P.A., Schwab M.E. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J. Cell Biol. 1999, 144:373-384.
43. Montgomery N., Hill A., McFarlane S., Neisen J., O'Grady A., Conlon S., Jirstrom K., Kay E.W., Waugh D.J. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res. 2012, 14:R84.
44. Merzak A., Koocheckpour S., Pilkington G.J. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res. 1994, 54:3988-3992.
45. Stamenkovic I., Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J. Invest. Dermatol. 2009, 129:1321-1324.
46. Ariza A., Lopez D., Mate J.L., Isamat M., Musulen E., Pujol M., Ley A., Navas-Palacios J.J. Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum. Pathol. 1995, 26:1144-1147.
47. Marrero-Diaz R., Bravo-Cordero J.J., Megias D., Garcia M.A., Bartolome R.A., Teixido J., Montoya M.C. Polarized MT1-MMP-CD44 interaction and CD44 cleavage during cell retraction reveal an essential role for MT1-MMP in CD44-mediated invasion. Cell Motil. Cytoskeleton 2009, 66:48-61.
48. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H., Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 2001, 153:893-904.
49. Belkin A.M., Akimov S.S., Zaritskaya L.S., Ratnikov B.I., Deryugina E.I., Strongin A.Y. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J. Biol. Chem. 2001, 276:18415-18422.
50. Belkin A.M., Zemskov E.A., Hang J., Akimov S.S., Sikora S., Strongin A.Y. Cell-surface-associated tissue transglutaminase is a target of MMP-2 proteolysis. Biochemistry 2004, 43:11760-11769.
51. Spuch C., Ortolano S., Navarro C. LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease. Front. Physiol. 2012, 3:269.
52. Rozanov D.V., Hahn-Dantona E., Strickland D.K., Strongin A.Y. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J. Biol. Chem. 2004, 279:4260-4268.
53. Selvais C., D'Auria L., Tyteca D., Perrot G., Lemoine P., Troeberg L., Dedieu S., Noel A., Nagase H., Henriet P., Courtoy P.J., Marbaix E., Emonard H. Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J 2011, 25:2770-2781.
54. Xu Y., Yuan J., Zhang Z., Lin L., Xu S. Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis. Mol. Biol. Rep. 2012, 39:8979-8985.
55. Endo K., Takino T., Miyamori H., Kinsen H., Yoshizaki T., Furukawa M., Sato H. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 2003, 278:40764-40770.
56. Su G., Blaine S.A., Qiao D., Friedl A. Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res. 2008, 68:9558-9565.
57. Xie H., Xue Y.X., Liu L.B., Wang P., Liu Y.H., Ying H.Q. Expressions of matrix metalloproteinase-7 and matrix metalloproteinase-14 associated with the activation of extracellular signal-regulated kinase1/2 in human brain gliomas of different pathological grades. Med. Oncol. 2011, 28(Suppl. 1):S433-S438.
58. Takino T., Tsuge H., Ozawa T., Sato H. MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem. Biophys. Res. Commun. 2010, 396:1042-1047.
59. Golubkov V.S., Chekanov A.V., Doxsey S.J., Strongin A.Y. Centrosomal pericentrin is a direct cleavage target of membrane type-1 matrix metalloproteinase in humans but not in mice: potential implications for tumorigenesis. J. Biol. Chem. 2005, 280:42237-42241.
60. Golubkov V.S., Boyd S., Savinov A.Y., Chekanov A.V., Osterman A.L., Remacle A., Rozanov D.V., Doxsey S.J., Strongin A.Y. Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J. Biol. Chem. 2005, 280:25079-25086.
61. Eisenach P.A., Roghi C., Fogarasi M., Murphy G., English W.R. MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J. Cell Sci. 2010, 123:4182-4193.
62. Lamszus K., Brockmann M.A., Eckerich C., Bohlen P., May C., Mangold U., Fillbrandt R., Westphal M. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res. 2005, 11:4934-4940.
63. Chun T.H., Sabeh F., Ota I., Murphy H., McDonagh K.T., Holmbeck K., Birkedal-Hansen H., Allen E.D., Weiss S.J. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 2004, 167:757-767.
64. Aplin A.C., Zhu W.H., Fogel E., Nicosia R.F. Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis. Am. J. Physiol. Cell Physiol. 2009, 297:C471-C480.
65. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58:1048-1051.
66. Groft L.L., Muzik H., Rewcastle N.B., Johnston R.N., Knauper V., Lafleur M.A., Forsyth P.A., Edwards D.R. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br. J. Cancer 2001, 85:55-63.
67. Mohanam S., Wang S.W., Rayford A., Yamamoto M., Sawaya R., Nakajima M., Liotta L.A., Nicolson G.L., Stetler-Stevenson W.G., Rao J.S. Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin. Exp. Metastasis 1995, 13:57-62.
68. Aaberg-Jessen C., Christensen K., Offenberg H., Bartels A., Dreehsen T., Hansen S., Schroder H.D., Brunner N., Kristensen B.W. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J. Neurooncol. 2009, 95:117-128.
69. Nakano A., Tani E., Yamamoto Y., Furuyama J., Miyazaki K. [Increased expression of gelatinases A and B, matrilysin and TIMP-1 genes in human malignant gliomas], Nihon rinsho. Nippon Rinsho 1995, 53:1816-1821.
70. Will H., Atkinson S.J., Butler G.S., Smith B., Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 1996, 271:17119-17123.
71. Butler G.S., Butler M.J., Atkinson S.J., Will H., Tamura T., Schade van Westrum S., Crabbe T., Clements J., d'Ortho M.P., Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 1998, 273:871-880.
72. Goldberg G.I., Marmer B.L., Grant G.A., Eisen A.Z., Wilhelm S., He C.S. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:8207-8211.
73. Howard E.W., Banda M.J. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J. Biol. Chem. 1991, 266:17972-17977.
74. Butler G.S., Apte S.S., Willenbrock F., Murphy G. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J. Biol. Chem. 1999, 274:10846-10851.
75. Simpson K.S., Komar C.M., Curry T.E. Localization and expression of tissue inhibitor of metalloproteinase-4 in the immature gonadotropin-stimulated and adult rat ovary. Biol. Reprod. 2003, 68:214-221.
76. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., Nishimura S., Imamura Y., Kitayama H., Alexander D.B., Ide C., Horan T.P., Arakawa T., Yoshida H., Nishikawa S., Itoh Y., Seiki M., Itohara S., Takahashi C., Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800.
77. Dong Q., Yu D., Yang C.M., Jiang B., Zhang H. Expression of the reversion-inducing cysteine-rich protein with Kazal motifs and matrix metalloproteinase-14 in neuroblastoma and the role in tumour metastasis. Int. J. Exp. Pathol. 2010, 91:368-373.
78. Silveira Correa T.C., Massaro R.R., Brohem C.A., Taboga S.R., Lamers M.L., Santos M.F., Maria-Engler S.S. RECK-mediated inhibition of glioma migration and invasion. J. Cell. Biochem. 2010, 110:52-61.
79. Golan K., Vagima Y., Goichberg P., Gur-Cohen S., Lapidot T. MT1-MMP and RECK: opposite and essential roles in hematopoietic stem and progenitor cell retention and migration. J. Mol. Med. 2011, 89:1167-1174.
80. Deryugina E.I., Ratnikov B., Monosov E., Postnova T.I., DiScipio R., Smith J.W., Strongin A.Y. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res. 2001, 263:209-223.
81. Atobe K., Ishida T., Ishida E., Hashimoto K., Kobayashi H., Yasuda J., Aoki T., Obata K., Kikuchi H., Akita H., Asai T., Harashima H., Oku N., Kiwada H. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol. Pharm. Bull. 2007, 30:972-978.
82. Fortier S., Touaibia M., Lord-Dufour S., Galipeau J., Roy R., Annabi B. Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells. Glycobiology 2008, 18:195-204.
83. Zarrabi K., Dufour A., Li J., Kuscu C., Pulkoski-Gross A., Zhi J., Hu Y., Sampson N.S., Zucker S., Cao J. Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J. Biol. Chem. 2011, 286:33167-33177.
84. Puli S., Lai J.C., Bhushan A. Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J. Neurooncol. 2006, 79:135-142.
85. Annabi B., Laflamme C., Sina A., Lachambre M.P., Beliveau R. A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells. J. Neuroinflammation 2009, 6:8.
86. Annabi B., Lachambre M.P., Bousquet-Gagnon N., Page M., Gingras D., Beliveau R. Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim. Biophys. Acta 2002, 1542:209-220.
87. Annabi B., Shedid D., Ghosn P., Kenigsberg R.L., Desrosiers R.R., Bojanowski M.W., Beaulieu E., Nassif E., Moumdjian R., Beliveau R. Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. J. Vasc. Surg. 2002, 35:539-546.
88. Zhang H., Qi M., Li S., Qi T., Mei H., Huang K., Zheng L., Tong Q. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol. Cancer Ther. 2012, 11:1454-1466.
89. Markovic D.S., Vinnakota K., van Rooijen N., Kiwit J., Synowitz M., Glass R., Kettenmann H. Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav. Immun. 2011, 25:624-628.
90. Tan M.L., Choong P.F., Dass C.R. DNAzyme delivery systems: getting past first base. Expert Opin. Drug Discovery 2009, 6:127-138.
91. Devy L., Huang L., Naa L., Yanamandra N., Pieters H., Frans N., Chang E., Tao Q., Vanhove M., Lejeune A., van Gool R., Sexton D.J., Kuang G., Rank D., Hogan S., Pazmany C., Ma Y.L., Schoonbroodt S., Nixon A.E., Ladner R.C., Hoet R., Henderikx P., Tenhoor C., Rabbani S.A., Valentino M.L., Wood C.R., Dransfield D.T. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009, 69:1517-1526.
92. Nyalendo C., Sartelet H., Gingras D., Beliveau R. Inhibition of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation blocks tumor progression in mice. Anticancer Res. 2010, 30:1887-1895.
93. Levin V.A., Phuphanich S., Yung W.K., Forsyth P.A., Maestro R.D., Perry J.R., Fuller G.N., Baillet M. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J. Neuro Oncol. 2006, 78:295-302.
94. Groves M.D., Puduvalli V.K., Hess K.R., Jaeckle K.A., Peterson P., Yung W.K., Levin V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002, 20:1383-1388.
95. Kucharzewska P., Christianson H.C., Welch J.E., Svensson K.J., Fredlund E., Ringner M., Morgelin M., Bourseau-Guilmain E., Bengzon J., Belting M. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7312-7317.
96. Kucharzewska P., Belting M. Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J. Extracell. Vesicles 2013, 2.
97. D'Asti E., Garnier D., Lee T.H., Montermini L., Meehan B., Rak J. Oncogenic extracellular vesicles in brain tumor progression. Front. Physiol. 2012, 3:294.
98. Turola E., Furlan R., Bianco F., Matteoli M., Verderio C. Microglial microvesicle secretion and intercellular signaling. Front. Physiol. 2012, 3:149.
99. Cossetti C., Smith J.A., Iraci N., Leonardi T., Alfaro-Cervello C., Pluchino S. Extracellular membrane vesicles and immune regulation in the brain. Front. Physiol. 2012, 3:117.